Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Up 6.5% – Here’s What Happened

16 Jan 2026, 20:26 by Teresa Graham · The Cerbat Gem

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report)’s stock price was up 6.5% on Wednesday . The company traded as high as $13.41 and last traded at $13.4240. Approximately 215,435 shares were traded during trading, a decline of 86% from the average daily volume of 1,523,653 shares. The stock had previously closed at $12.60.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMLX. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Citigroup lifted their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright boosted their price objective on Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a report on Friday, November 7th. Robert W. Baird increased their target price on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Finally, Bank of America raised their target price on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.25.

Get Our Latest Research Report on Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Stock Up 5.8%

The stock has a fifty day moving average of $13.01 and a 200-day moving average of $11.50.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. As a group, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Insider Activity

In other news, Director Karen Firestone purchased 8,100 shares of the firm’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was bought at an average price of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the purchase, the director directly owned 63,100 shares of the company’s stock, valued at $785,595. The trade was a 14.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Camille L. Bedrosian sold 6,580 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $14.35, for a total value of $94,423.00. Following the transaction, the insider directly owned 175,756 shares of the company’s stock, valued at approximately $2,522,098.60. This represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 17,621 shares of company stock worth $216,934 in the last ninety days. 12.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its position in shares of Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after buying an additional 2,487,617 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Amylyx Pharmaceuticals by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after acquiring an additional 143,065 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Amylyx Pharmaceuticals in the second quarter valued at $1,541,000. Los Angeles Capital Management LLC acquired a new position in Amylyx Pharmaceuticals in the second quarter valued at $149,000. Finally, Acadian Asset Management LLC boosted its stake in Amylyx Pharmaceuticals by 135.1% in the second quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock valued at $3,645,000 after acquiring an additional 326,976 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.